Results 281 to 290 of about 27,891 (313)

Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.

The Lancet
BACKGROUND Heart failure with mildly reduced or preserved ejection fraction (hereafter referred to as HFpEF) is the most common type of heart failure and is associated with a high risk of hospitalisation and death, especially in patients with overweight,
M. Kosiborod, J. Deanfield, R. Pratley, B. Borlaug, Javed Butler, M. Davies, S. Emerson, S. Kahn, D. Kitzman, I. Lingvay, Kenneth W. Mahaffey, Mark C. Petrie, J. Plutzky, S. Rasmussen, Cecilia Rönnbäck, Sanjiv J. Shah, Subodh Verma, P. E. Weeke, A. M. Lincoff   +18 more
semanticscholar   +1 more source

Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy

JAMA ophthalmology
This cohort study investigates the association between semaglutide use and nonarteritic anterior ischemic optic neuropathy.
Cindy X Cai, Michelle Hribar, Sally L. Baxter, Kerry E. Goetz, S. Swaminathan, Alexis Flowers, Eric N. Brown, Brian C. Toy, Benjamin Y Xu, John Chen, Aiyin Chen, Sophia Y Wang, Cecilia S. Lee, Theodore Leng, Joshua R. Ehrlich, A. Barkmeier, Karen R. Armbrust, Michael V. Boland, David A Dorr, D. Boyce, Thamir M. Alshammari, J. Swerdel, M. Suchard, M. Schuemie, F. Bu, A. Sena, G. Hripcsak, Akihiko Nishimura, Paul Nagy, T. Falconer, Scott L. DuVall, M. Matheny, Benjamin Viernes, William J O'Brien, Linying Zhang, Benjamin Martin, Erik Westlund, N. Mathioudakis, Ruochong Fan, Adam Wilcox, Albert Lai, Jacqueline C Stocking, Sahar Takkouche, Lok Hin Lee, Yangyiran Xie, Izabelle Humes, David B. McCoy, M. Adibuzzaman, Raymond G Areaux, William Rojas-Carabali, J. Brash, David A Lee, N. Weiskopf, Louise Mawn, Rupesh Agrawal, Hannah Morgan-Cooper, Priya Desai, Patrick B. Ryan   +57 more
semanticscholar   +1 more source

Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes

Diabetes Technology & Therapeutics
Objective: Adults with type 1 diabetes (T1D) are increasingly overweight or obese, in part due to intensive insulin therapy. Newer non-insulin medications targeting both hyperglycemia and weight loss are approved for people with type 2 diabetes.
Janet K. Snell-Bergeon, Gurleen Kaur, Drew C Renner, H. Akturk, C. Beatson, Satish K Garg   +5 more
semanticscholar   +1 more source

Modulation of metabolic, inflammatory and fibrotic pathways by semaglutide in metabolic dysfunction-associated steatohepatitis

Nature Medicine
Metabolic dysfunction-associated steatohepatitis (MASH) is a chronic liver disease strongly associated with cardiometabolic risk factors. Semaglutide, a glucagon-like peptide-1 receptor agonist, improves liver histology in MASH, but the underlying ...
Maximilian Jara, Jenny Norlin, M. Kjær, Kasper Almholt, K. Bendtsen, Elisabetta Bugianesi, K. Cusi, E. Galsgaard, M. Geybels, L. Gluud, L. M. Harder, R. Loomba, G. Mazzoni, Philip N. Newsome, L. Nitze, MS Palle, V. Ratziu, A. Sejling, V. W. Wong, Q. Anstee, L. Knudsen   +20 more
semanticscholar   +1 more source

Impact of Semaglutide on fat mass, lean mass and muscle function in patients with obesity: The SEMALEAN study

Diabetes, obesity and metabolism
Semaglutide, a GLP‐1 receptor agonist, has shown efficacy in promoting weight loss. However, limited data exist on its impact on lean mass, muscle function, and metabolic adaptations.
M. Alissou, T. Demangeat, V. Folope, H. Van Elslande, Hélène Lelandais, J. Blanchemaison, Pierre-Emmanuel Cailleaux, S. Guney, A. Aupetit, Agnès Aubourg, Clément Rapp, A. Petit, Morgane Godin, Luc Vignal, S. Grigioni, P. Déchelotte, G. Colange, M. Coëffier, N. Achamrah   +18 more
semanticscholar   +1 more source

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial

Biomolecules
Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease.
Jelena Petković-Dabić, I. Binić, Bojana Carić, L. Božić, Sanja Umičević-Šipka, Nataša Bednarčuk, Saša Dabić, Mirna Šitum, Snježana Popović-Pejičić, M. Stojiljković, R. Škrbić   +10 more
semanticscholar   +1 more source

Oral Semaglutide and Cardiovascular Outcomes in People With Type 2 Diabetes, According to SGLT2i Use: Prespecified Analyses of the SOUL Randomized Trial

Circulation
BACKGROUND: Both GLP-1 (glucagon-like peptide-1) receptor agonists and SGLT2 (sodium-glucose cotransporter-2) inhibitors (SGLT2i) improve cardiovascular outcomes in people with type 2 diabetes and cardiovascular or chronic kidney disease.
MD Nikolaus Marx, MD John E. Deanfield, MD Johannes F.E. Mann, MD Rosario Arechavaleta, MD Stephen C. Bain, MD Harpreet S. Bajaj, MD Katrine Bayer Tanggaard, MD Andreas L. Birkenfeld, MD John B. Buse, MD Zaklina Davicevic-Elez, MD Cyrus Desouza, PhD Scott S. Emerson, Mads, MD D.M. Engelmann, MD G. Kees Hovingh, MD Silvio E. Inzucchi, PhD Pardeep S. Jhund, MD Sharon L. Mulvagh, MD Rodica Pop-Busui, PhD Neil R. Poulter, FMedSci Søren Rasmussen, Pei-Ju Tu, M. McGuire   +22 more
semanticscholar   +1 more source

Ophthalmic Complications Associated With the Antidiabetic Drugs Semaglutide and Tirzepatide.

JAMA ophthalmology
Importance Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.
Bradley J. Katz, Michael S. Lee, Norah S Lincoff, Anne S. Abel, Somya Chowdhary, Brian D. Ellis, A. Najafi, John Nguyen, Meagan D Seay, Judith E. A. Warner   +9 more
semanticscholar   +1 more source

Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.

The Lancet
BACKGROUND The SELECT trial found semaglutide reduced major adverse cardiovascular events (MACE) in patients with overweight or obesity with cardiovascular disease but without diabetes.
J. Deanfield, A. M. Lincoff, S. Kahn, S. Emerson, I. Lingvay, Benjamin M. Scirica, J. Plutzky, Robert F. Kushner, Helen M. Colhoun, G. Hovingh, S. Stensen, P. E. Weeke, O. Jeppesen, Rafael Bravo, Chau-Chung Wu, Issei Komuro, Ferruccio Santini, J. Hjelmesæth, Miguel Urina-Triana, Silvio Buscemi, D. Ryan   +20 more
semanticscholar   +1 more source

Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.

The Lancet Diabetes and Endocrinology
BACKGROUND Once-weekly subcutaneous semaglutide 2·4 mg is approved for weight management in people with obesity and related complications; however, some individuals do not reach their therapeutic goals with this dose.
Sean Wharton, Paula Freitas, J. Hjelmesæth, M. Kabisch, K. Kandler, I. Lingvay, María Quiroga, Julio Rosenstock, W. T. Garvey   +8 more
semanticscholar   +1 more source